Zytiga is the Darling of the Day. Really!

Zytiga was in news today, but more so were its competitors, Provenge and MDV3100. The big news was early unblinding of Zytiga trial in metastatic prostate cancer patients due to significant improvement seen in progression-free survival (PFS) and other endpoints.

MDV1300 Making a Mark While Provenge Takes a Deep Plunge

Today San Francisco-based Medivation, Inc., ($MDVN) saw its stock value scale El Capitan within a day.  This coming on the heels of Dendreon Corp. ($DNDN) losing a huge chunk of its stock value yesterday is a good example of human psychology.  We reward "optimism" over "cautious behavior."